Inactive Instrument

Funds and ETFs Intersect ENT, Inc.

Equities

XENT

US46071F1030

Medical Equipment, Supplies & Distribution

ETFs positioned on Intersect ENT, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.04% 509 M€ -.--%
Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.
More about the company
  1. Stock Market
  2. Equities
  3. XENT Stock
  4. Funds and ETFs Intersect ENT, Inc.